Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4

Citations Over TimeTop 20% of 2013 papers

Abstract

The human neuraminidase enzymes (hNEU) play important roles in human physiology and pathology. The lack of potent and selective inhibitors toward these enzymes has limited our understanding of their function and the development of therapeutic applications. Here we report the evaluation of a panel of compounds against the four human neuraminidase isoenzymes. Among the compounds tested, we identified the first selective, nanomolar inhibitors of the human neuraminidase 4 enzyme (NEU4). The most potent NEU4 inhibitor (5-acetamido-9-[4-hydroxymethyl[1,2,3]triazol-1-yl]-2,3,5,9-tetradeoxy-d-glycero-d-galacto-2-nonulopyranosonic acid) was found to have an inhibitory constant (K i ) of 30 ± 19 nM and was 500-fold selective for its target over the other hNEU isoenzymes tested in vitro (NEU1, NEU2, and NEU3). This is the first report of any inhibitor of hNEU with nanomolar potency, and this confirms that the 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA) scaffold can be exploited to develop new, potent, and selective inhibitors that target this important family of human enzymes.

Related Papers

• → Inhibition of sialidase activity as a therapeutic approach(2018)61 cited
• → Polymorphonuclear leukocytic sialic acid and sialidase activity in obesity(1997)2 cited
• → Analysis of neuraminidase isozyme phenotypes in mammalian tissues: An electrophoretic approach(1985)12 cited
• → Reappearance in vivo of neuraminidase-sensitive sialic acid in L 5222 rat leukemia cells(1976)4 cited
• → Blood plasma sialidase activity in CHD patients and healthy subjects is partially accounted for influenza virus neuraminidase(2020)